Loading, please wait...
University of South Carolina College of Pharmacy
Annual Continuing Education Conference
Day 2: Home Studies
Speakers and Topics:
* Please scroll down and expand all topics to view specific learning objectives for pharmacists.
Faculty
 |
Jordan Cooler, PharmD, BCPP; Clinical Assistant Professor, University of South Carolina College of Pharmacy; Psychiatric Pharmacist, University of South Carolina Student Health Center
|
Drugs of Abuse: A Focused Update on Abuse and Monitoring
|
| Educational Objectives: After completing this program, the pharmacist will be able to: 1. Identify risk factors for inappropriate use of controlled substances and other prescription and non-prescription drugs of abuse 2. Explain best practices for identifying and mitigating drug abuse and misuse based on available data 3. Apply recommendations in a specific pharmacy practice setting |
||
 |
Julie Sease, PharmD, FCCP; Senior Associate Dean and Professor,
University of South Carolina College of Pharmacy
|
Hypertension: Classification, Management, and Monitoring of the Most Common Disease State
|
|
Educational Objectives:
After completing this program, the pharmacist will be able to: 1. Use patient case information to categorize a patient as having normal blood pressure, elevated blood pressure, stage 1 hypertension, or stage 2 hypertension and assign an appropriate evidence based blood pressure goal for the patient 2. Recommend an appropriate initial evidence based treatment plan (including nonpharmacologic and pharmacologic therapies) for a patient based on their presenting blood pressure value and patient specific factors (including compelling indications, laboratory evaluation, and ASCVD risk) 3. Justify an appropriate evidence based treatment plan for a patient who is not meeting blood pressure goal on their current regimen 4. Educate a patient who will be conducting home blood pressure monitoring about the guideline-recommended way to complete this |
||
 |
Cynthia Phillips, PharmD, CDE; Clinical Associate Professor, University of South Carolina College of Pharmacy; Clinical Pharmacist, Prisma Health Richland
|
Determining Decisions and Deciphering Dilemmas in Dyslipidemia with Updated
American College of Cardiology/American Heart Association Cholesterol Guidelines |
| Educational Objectives: After completing this program, the pharmacist will be able to: 1. Investigate patient risk of atherosclerotic cardiovascular disease (ASCVD) using risk calculators and risk enhancing factors 2. Analyze updates in the American College of Cardiology (ACC) /American Heart Association (AHA) Cholesterol Guidelines 3. Discuss the appropriate use of non-statin therapies in ASCVD prevention 4. Apply updated ACC/AHA Cholesterol Guidelines to patient cases |
||
 |
Brie Dunn, PharmD; Associate Dean for Outcomes Assessment &
Accreditation and Clinical Associate Professor, University of South Carolina College of Pharmacy
|
Beyond Diabetes: Benefits of SGLT2 Inhibitors and GLP-1 Agonists
|
| Educational Objectives: After completing this program, the pharmacist will be able to: 1. Describe the advantages and disadvantages of SGLT2 inhibitors and GLP-1 agonists 2. Identify potential benefits of SGLT2 inhibitors and GLP-1 agonists based on recent clinical trial data 3. Compare and contrast cardiovascular and renal benefits for available SGLT2 inhibitors and GLP-1 agonists 4. Develop and justify an evidence-based plan for a specific patient in order to provide cardiovascular and/or renal benefit. given a case scenario |
||
 |
Hana Rac Winders, PharmD, BCIDP; Lead Antimicrobial Stewardship Pharmacist, Antimicrobial Stewardship Collaborative of South Carolina (ASC- SC); Clinical Assistant Professor, University of South Carolina College of Pharmacy
|
Community Acquired Pneumonia Update
|
| Educational Objectives: After completing this program, the pharmacist will be able to: 1. Identify the differences between the 2007 and 2019 community-acquired pneumonia (CAP) guidelines 2. Discuss the evidence behind recommendations in the new CAP guidelines 3. Apply the new CAP guidelines to patient cases 4. Recognize the pharmacist's role in antimicrobial stewardship relating to the treatment of CAP |
||
 |
Jill Michels, PharmD, DABAT; Clinical Associate Professor, University of South Carolina College of Pharmacy; Managing Director, Palmetto Poison Center
|
Management of Pit Viper and Black Widow Envenomation
|
| Educational Objectives: After completing this program, the pharmacist will be able to: 1. Discuss treatment myths associated with pit viper envenomation. 2. Recommend supportive treatment for pit viper envenomation. 3. Compare Crotalidae Polyvalent Immune Fab (Ovine) antivenom to Crotalidae Immune F(ab’)2 (Equine) antivenom 4. List treatment options for black widow spider bite |
Registration Fees
|
|
Hours | Pharmacists |
|
Entire Program:
To Purchase the entire program,
click on "Purchase Now" below!
|
7 hours
|
$75 |
|
Individual Sessions
To purchase individual sessions, check the session(s) you would like to purchase on the list below!
|
1-6 hours | $15 per session |
CE Categories: This program was recorded and adapted from a live activty at the UofSC COP Annual Continuing Education Conference in Columbia, SC on February 22, 2020. Six hours qualify as “drug therapy or patient management”, with one of those hours designed to combat the opioid epidemic through pain management and “approved procedures for monitoring controlled substances”. The video presentations are 1 hour long each, and there is a required 4 question post-test after the recording has been viewed.
How to Earn Credit: Participants must 1) read the learning objectives and faculty disclosures, 2) listen to the video presentation and the interactivity, and 3) complete the posttest with a score of at least 70% and the evaluation form. To receive credit, you must provide your date of birth and NABP number. CE credit will be submitted to the NABP CE Monitor.
Required Computer Hardware/Software
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows, Mac OS and Linux
- Internet Browser: Internet Explorer 7.0 or higher; Mozilla Firefox 3.0 or higher; Google Chrome
- Computer Speakers or headphones connected to your computer
- Broadband Internet Connection: Cable, High-speed DSL or T1
- Monitor Screen Resolution: 320x480 or higher
- Media Viewing Requirements: Adobe Reader, Adobe Flash Player, Microsoft Power Point and HTML
Privacy and Confidentiality: Information received by the University of South Carolina College of Pharmacy for continuing education (CE) programs will be maintained in a confidential and secure manner. In order for continuing education credit to be submitted to the NABP CPE Monitor, personal information such as your NABP e-Profile ID and day and month of birth will be required along with your name and contact information.
Provider Contact Information: For questions regarding this continuing education activity, please contact our office at CE@cop.sc.edu or 803-777-9979.
Fee
$75.00
CE Hours
6.00
CE Units
0.600
Activity Type
- Knowledge-Based and Application-Based
Target Audience(s)
- Pharmacists
Accreditation(s)
|
The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
Participants must sign in upon arrival and have attendance verified.
To claim credit for this activity, participants must complete the online program evaluations and must update their accounts to properly reflect their month/day of birth and correct NABP e-Profile ID. To register with NABP or look up your NABP e-Profile ID, please click on the CPE Monitor logo below to be directed to their site.
Credit that is claimed greater than 60 days from the date of the program will be automatically rejected by the CPE Monitor. Claiming credit within 30 days of the live program will ensure that any issues with transmission to the CPE Monitor can be rectified in advance of the 60-day deadline. If you would like a paper statement of credit, you may print an individual statement or a transcript from your NABP e-Profile.
Support/Credits
Financial Disclosure: UofSC COP has a full and fair disclosure policy that requires course planners and faculty to communicate any real or apparent commercial affiliations related to the content of their presentation and materials. Participants are advised that the accredited status of UofSC COP does not imply endorsement by the provider of ACPE of any products/therapeutics mentioned in this course. The information in this course is for educational purposes only.
Dr. Cooler has indicated no relevant financial relationships.
Dr. Sease has indicated no relevant financial relationships.
Dr. Phillips has indicated no relevant financial relationships.
Dr. Dunn has indicated no relevant financial relationships.
Dr. Winders has indicated the following financial relationships: Honoraria - Speaker: Biomerieux.
Dr. Michels has indicated no relevant financial relationships.
At the completion of this activity, the participant will be able to:
- Identify risk factors for inappropriate use of controlled substances and other prescription and non-prescription drugs of abuse
- Explain best practices for identifying and mitigating drug abuse and misuse based on available data
- Apply recommendations in a specific pharmacy practice setting
Speaker(s)/Author(s)
|
Jordan Cooler Haygood, PharmD, BCPP
|
Activity Number
0062-0000-20-007-H01-P
Release Date:
Feb 22, 2020
Credit Expiration Date:
Feb 22, 2023
CE Hours
1.00
Fee
$15.00
At the completion of this activity, the participant will be able to:
- Use patient case information to categorize a patient as having normal blood pressure, elevated blood pressure, stage 1 hypertension, or stage 2 hypertension and assign an appropriate evidence based blood pressure goal for the patient
- Recommend an appropriate initial evidence based treatment plan (including nonpharmacologic and pharmacologic therapies) for a patient based on their presenting blood pressure value and patient specific factors (including compelling indications, laboratory evaluation, and ASCVD risk)
- Justify an appropriate evidence based treatment plan for a patient who is not meeting blood pressure goal on their current regimen
- Educate a patient who will be conducting home blood pressure monitoring about the guideline-recommended way to complete this
Speaker(s)/Author(s)
|
Julie Sease, PharmD, FCCP, BCPS, CDE, BCACP
|
Activity Number
0062-0000-20-008-H01-P
Release Date:
Feb 22, 2020
Credit Expiration Date:
Feb 22, 2023
CE Hours
1.00
Fee
$15.00
At the completion of this activity, the participant will be able to:
- Investigate patient risk of atherosclerotic cardiovascular disease (ASCVD) using risk calculators and risk enhancing factors
- Analyze updates in the American College of Cardiology (ACC) /American Heart Association (AHA) Cholesterol Guidelines
- Discuss the appropriate use of non-statin therapies in ASCVD prevention
- Apply updated ACC/AHA Cholesterol Guidelines to patient cases
Speaker(s)/Author(s)
|
Cynthia Phillips, PharmD, CDCES
|
Activity Number
0062-0000-20-009-H01-P
Release Date:
Feb 22, 2020
Credit Expiration Date:
Feb 22, 2023
CE Hours
1.00
Fee
$15.00
At the completion of this activity, the participant will be able to:
- Describe the advantages and disadvantages of SGLT2 inhibitors and GLP-1 agonists
- Identify potential benefits of SGLT2 inhibitors and GLP-1 agonists based on recent clinical trial data
- Compare and contrast cardiovascular and renal benefits for available SGLT2 inhibitors and GLP-1 agonists
- Develop and justify an evidence-based plan for a specific patient in order to provide cardiovascular and/or renal benefit. given a case scenario
Speaker(s)/Author(s)
|
Brie Dunn, PharmD
|
Activity Number
0062-0000-20-010-H01-P
Release Date:
Feb 22, 2020
Credit Expiration Date:
Feb 22, 2023
CE Hours
1.00
Fee
$15.00
At the completion of this activity, the participant will be able to:
- Identify the differences between the 2007 and 2019 community-acquired pneumonia (CAP) guidelines
- Discuss the evidence behind recommendations in the new CAP guidelines
- Apply the new CAP guidelines to patient cases
- Recognize the pharmacist's role in antimicrobial stewardship relating to the treatment of CAP
Speaker(s)/Author(s)
|
Hana Rac Winders, PharmD, BCIDP
|
Activity Number
0062-0000-20-011-H01-P
Release Date:
Feb 22, 2020
Credit Expiration Date:
Feb 22, 2023
CE Hours
1.00
Fee
$15.00
At the completion of this activity, the participant will be able to:
- Discuss treatment myths associated with pit viper envenomation.
- Recommend supportive treatment for pit viper envenomation.
- Compare Crotalidae Polyvalent Immune Fab (Ovine) antivenom to Crotalidae Immune F(ab’)2 (Equine) antivenom
- List treatment options for black widow spider bite
Speaker(s)/Author(s)
|
Jill Michels, PharmD, DABAT
|
Activity Number
0062-0000-20-012-H01-P
Release Date:
Feb 22, 2020
Credit Expiration Date:
Feb 22, 2023
CE Hours
1.00
Fee
$15.00